Eli Lilly and Company

Array Biopharma Inc.

Genentech, Inc.

Hongqi Tian

Thomas Daniel Aicher

Jeongbeob Seo

Owen Brendan Wallace

Jason De Meese

James F Blake

Steven Armen Boyd

Thomas Edward Mabry

Mark Joseph Chicarelli

Leonard Larry Winneroski, Jr

John Joseph Gaudino

Ronald Jay Hinklin

Wendy B Young

Allison L Marlow

Nancy June Snyder

Allen A Thomas

Alexandre Joseph Buckmelter

Li Ren

David A Moreno

Ellen Ruth Laird

Bainian Feng

Frederick Cohen

John Gordon Allen

Yanping Xu

Jefferson Ray McCowan

Brad Newhouse

Kin Chiu Fong

Peter Biagio Anzeveno

Simon Mathieu

Janet Gunzner

Zhaogen Chen

Gregory Alan Stephenson

Joachim Rudolph

Jonas Grina

Renhua Li

Zhaoyang Wen

Ashraf Saeed

Steven Mark Wenglowsky

Alexei Pavlovych Krasutsky

Kateri Ahrendt

Kim Malesky

Joshua D Hansen

Paul Lunghofer

Tomas Kaplan

Leonard Larry Junior Winneroski

Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. 

Pyrazole [3, 4-B] pyridine Raf inhibitors

Compounds of Formula I and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula I and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. 

Heterobicyclic thiophene compounds and methods of use

The present invention discloses novel compounds of Formula (I): having 11&#x3b2;-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I), as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11&#x3b2;-HSD type 1 activity. 

Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1

The present invention provides compounds of formula I that are useful as potent and selective inhibitors of 11-beta hydroxysteroid dehydrogenase 1. The present invention further provides a pharmaceutical composition which comprises a compound of Formula I, or a pharmaceutical salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient. In addition, the present invention provides compositions comprising compounds of formula I for the treatment of metabolic syndrome, diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, other symptoms associated with hyperglycemia, and related disorders. Formula (I) wherein, Ris (II), or (III) Gis methylene or ethylene; L is a divalent linking group selected from &#x2014;(C-C) alkylene-, &#x2014;S&#x2014;, &#x2014;CH(OH)&#x2014;, or &#x2014;O&#x2014;; A is methylene, &#x2014;S&#x2014;, &#x2014;O&#x2014;, or &#x2014;NH&#x2014;; and the other substituents are as defined in the claims. 

Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1

Compounds of Formulas Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. 

Heterobicyclic pyrazole compounds and methods of use

The present invention discloses compounds of Formula I: (I) having 11beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as the use of the Formula I and compositions as medicaments to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, Syndrome X, and other conditions associated with hyperglycemia. 

Growing community of inventors

Longmont, CO, United States of America

Hongqi Tian